

MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/5/2011; page 1

Suggested Formula	Hydromorphone Hydrochloride 0.2 mg/mL Epidural Injection (Solution, 100 mL)	FIN	F 003 716v2
----------------------	---	-----	-------------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Hydromorphone Hydrochloride 10 mg/mL Injection (Sterile, Preservative Free)	2.00	mL				
Sodium Chloride 0.9% for Injection, USP (Sterile, Preservative Free)	98.0	mL				

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information		
Light sensitive (protect from lig	ght whenever possible):	Hydromorphone Hydrochloride
Controlled substance (adhere to documentation procedures)	o proper handling and	Hydromorphone Hydrochloride
Suggested Preparatory Guidelines		O
Non-Sterile Preparati	on Sterile Preparation	
Processing Error / Testing Considerations:		sterility and endotoxin testing considerations during asure an additional 5 to 9% of the required quantities
Special Instruction:	environmental conditions, following	thin the appropriate facilities under adequate ng the necessary guidelines and procedures as stated qualified personnel must prepare this formula.
	All heat stable, reusable materials by dry heat sterilization at 250°C	and equipment must be sterilized and depyrogenated for 2 hours prior to use.
	Every batch of final product compendotoxin tested before being disp	bounded using this procedure must be sterility and pensed.
		le gown, sterile gloves, shoe covers, head cap, lways be worn. In addition, proper personnel tering the buffer or clean area.
	~ ·	by performing a filter stress test. If the test be defective, the solution must be discarded and
		f very small quantities of ingredients. All calculations be verified before dispensing the final product.



MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/5/2011; page 2

Suggested Formula	Hydromorphone Hydrochloride 0.2 mg/mL Epidural Injection (Solution, 100 mL)	FIN	F 003 716v2
----------------------	---	-----	-------------

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing		Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Hydromorphone Hydrochloride 10 mg/mL Injection (Sterile, Preservative Free) §	2.00	mL			
Sodium Chloride 0.9% for Injection, USP (Sterile, Preservative Free) §	98.0	mL	(A)		

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.

	Preparatory Instruction
	IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique
1.	Equipment sterilization:
	Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and
	equipment, then return to ambient temperature.
2.	Medium integration:
	Note: All manipulations must be done under a laminar airflow hood. Disinfect the commercial vials with Alcohol 70% prior to withdrawing the required amount of liquid.
	A. Incrementally add the Hydromorphone Hydrochloride 10 mg/mL Injection (Sterile, Preservative Free) to the Sodium Chloride 0.9% for Injection (Sterile, Preservative Free).
	Specifications: Continuously mix.
	End result: Homogeneous liquid-like solution.
3.	Filtering and transferring:
	Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.
4.	Filter integrity test:
	Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.
5.	Sterility testing:
	Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.



MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/5/2011; page 3

Suggested Formula	Hydromorphone Hydrochloride 0.2 mg/mL Epidural Injection (Solution, 100 mL)	FIN	F 003 716v2	
----------------------	---	-----	-------------	--

SUGGESTED PRESENTATION

GGESTED FRI		MIAHON			
Estimated Beyond-Use Date		14 days, refrigerated, as per USP. BUD based on a successful sterility and endotoxin test result.	Packa Requiren		Sterile, tightly closed, light-resistant unit-dose injection vials.
	1	Use as directed. Do not exceed dose.	l prescribed	8	Do not used if product changes color.
	2	Keep out of reach of children.		9	Protect from light.
	3	Keep refrigerated. Do not freeze		10	Preservative free solution, single use only. Discard any unused portion.
Auxiliary	4	Do not take with alcohol, tranquilizers or other CNS depre		11	May produce psychological and/or physical dependence.
Labels	5	Discard in the presence of matter.	particulate	12	Controlled substance. Dangerous unless used as directed.
	6	Consult your health care practit other prescription or over medications are currently being prescribed for future use.	-the-counter	13	May impair mental and/or physical ability. Use care when operating a car or machinery.
	7	For medical office use only.	7		
Pharmacist	Ad	d any auxiliary labels specific to t	he active ingr	edien	ts to the dispensing container as deemed necessary.
Instructions IMPORTANT: TO BE ADMINISTERED ONLY BY THE PRESCRIBING PHYSICI					Y BY THE PRESCRIBING PHYSICIAN.
Patient Instructions	Co	ntact your pharmacist in the event	of adverse re	action	ns.



MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/5/2011; page 4

Suggested Formula	Hydromorphone Hydrochloride 0.2 mg/mL Epidural Injection (Solution, 100 mL)	FIN	F 003 716v2
----------------------	---	-----	-------------

REFERENCES

1.	USP <797>. <i>United States Pharmacopeia XXXI / National Formulary 26.</i> Rockville, MD. US Pharmacopeial Convention, Inc. 2008.
2.	Parenteral Preparations. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 313.
3.	Hydromorphone (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #4803.
4.	Hydromorphone Hydrochloride. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 3rd Edition</i> . American Pharmaceutical Association; 2005: 216.
5.	Hydromorphone Hydrochloride (Monograph). <i>United States Pharmacopeia XXXI / National Formulary 26</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2008.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.